ROCK2/rasHa co-operation induces malignant conversion via p53 loss, elevated NF-κB and tenascin C-associated rigidity, but p21 inhibits ROCK2/NF-κB-mediated progression

Oncogene. 2017 May 4;36(18):2529-2542. doi: 10.1038/onc.2016.402. Epub 2016 Dec 19.

Abstract

To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT)-activated ROCK2 (K14.ROCKer) were crossed with mice expressing epidermal-activated rasHa (HK1.ras1205). At 8 weeks, 4HT-treated K14.ROCKer/HK1.ras1205 cohorts exhibited papillomas similar to HK1.ras1205 controls; however, K14.ROCKer/HK1.ras1205 histotypes comprised a mixed papilloma/well-differentiated squamous cell carcinoma (wdSCC), exhibiting p53 loss, increased proliferation and novel NF-κB expression. By 12 weeks, K14.ROCKer/HK1.ras1205 wdSCCs exhibited increased NF-κB and novel tenascin C, indicative of elevated rigidity; yet despite continued ROCK2 activities/p-Mypt1 inactivation, progression to SCC required loss of compensatory p21 expression. K14.ROCKer/HK1.ras1205 papillomatogenesis also required a wound promotion stimulus, confirmed by breeding K14.ROCKer into promotion-insensitive HK1.ras1276 mice, suggesting a permissive K14.ROCKer/HK1.ras1205 papilloma context (wound-promoted/NF-κB+/p53-/p21+) preceded K14.ROCKer-mediated (p-Mypt1/tenascin C/rigidity) malignant conversion. Malignancy depended on ROCKer/p-Mypt1 expression, as cessation of 4HT treatment induced disorganized tissue architecture and p21-associated differentiation in wdSCCs; yet tenascin C retention in connective tissue extracellular matrix suggests the rigidity laid down for conversion persists. Novel papilloma outgrowths appeared expressing intense, basal layer p21 that confined endogenous ROCK2/p-Mypt1/NF-κB to supra-basal layers, and was paralleled by restored basal layer p53. In later SCCs, 4HT cessation became irrelevant as endogenous ROCK2 expression increased, driving progression via p21 loss, elevated NF-κB expression and tenascin C-associated rigidity, with p-Mypt1 inactivation/actinomyosin-mediated contractility to facilitate invasion. However, p21-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 and rasHa/ROCK2/NF-κB signalling in skin carcinogenesis. Collectively, these data show that ROCK2 activation induces malignancy in rasHa-initiated/promoted papillomas in the context of p53 loss and novel NF-κB expression, whereas increased tissue rigidity and cell motility/contractility help mediate tumour progression.

MeSH terms

  • Animals
  • Carcinogenesis / genetics
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / pathology
  • Cell Differentiation / genetics
  • Cell Transformation, Neoplastic / genetics
  • Crosses, Genetic
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Keratinocytes / pathology
  • Keratinocytes / virology
  • Mice
  • NF-kappa B / genetics
  • Papilloma / genetics
  • Papilloma / pathology
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology
  • Tamoxifen / administration & dosage
  • Tamoxifen / analogs & derivatives
  • Tumor Suppressor Protein p53 / genetics*
  • p21-Activated Kinases / genetics*
  • rho-Associated Kinases / genetics*

Substances

  • NF-kappa B
  • Tumor Suppressor Protein p53
  • Tamoxifen
  • afimoxifene
  • Pak1 protein, mouse
  • Rock2 protein, mouse
  • p21-Activated Kinases
  • rho-Associated Kinases
  • Hras protein, mouse
  • Proto-Oncogene Proteins p21(ras)